Price/OCF Ratio: 35.38

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the Price/OCF ratio high or low?

The Price/OCF ratio of 35.38 is in line with its estimated 2-year average of 36.52, near the low end of its estimated 2-year range (20.71–94.23).

As of 2026-10-06T21:47:14.385Z. 11.15% below its estimated 12-month average of 39.82.

KRYS Price/OCF Ratio Metrics

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio FAQ

What is the Price/OCF ratio for Krystal Biotech, Inc. (KRYS)?

The Price/OCF ratio for KRYS stock is 35.38.

Is Krystal Biotech, Inc.'s Price/OCF ratio high or low?

The Price/OCF ratio of 35.38 is in line with its estimated 2-year average of 36.52, near the low end of its estimated 2-year range (20.71–94.23).

What is the estimated TTM average Price/OCF ratio for Krystal Biotech, Inc. (KRYS)?

The estimated TTM average Price/OCF ratio for KRYS stock is 39.82.

Showing the most recent 260 of 479 data points. The chart above shows the full history.

Related Metrics